Recombinant Production
| Category | Glossary |
|---|---|
| Also known as | Recombinant Peptides, Recombinant Protein Expression, Biosynthesis |
| Last updated | 2026-04-13 |
| Reading time | 4 min read |
| Tags | biochemistrymanufacturingbiologicsglossary |
Overview
Recombinant production uses living cells — most commonly Escherichia coli (E. coli) bacteria — to manufacture peptides and proteins. The gene encoding the desired peptide sequence is inserted into the host organism's DNA using recombinant DNA technology, and the organism's own cellular machinery then translates that gene into the target protein.
This approach is the standard manufacturing method for larger peptides (roughly 50+ amino acids), full-length proteins, and many approved biologic therapies including insulin, growth hormone, and erythropoietin.
Detailed Explanation
The Production Process
Gene construction. The DNA sequence encoding the target peptide is synthesized or cloned. Codon optimization — adjusting the DNA codons to match the host organism's preferred usage — can improve expression yields.
Vector insertion. The gene is inserted into an expression vector (a circular DNA plasmid) that contains regulatory elements: a promoter to drive transcription, a ribosome binding site, and often a selectable marker (such as antibiotic resistance) to identify successfully transformed cells.
Transformation. The expression vector is introduced into the host cell. For E. coli, this is commonly done by heat shock or electroporation.
Expression. The host cells are grown in fermentation tanks under controlled conditions (temperature, pH, oxygen, nutrient supply). When the culture reaches sufficient density, expression is induced — often by adding IPTG (isopropyl beta-D-1-thiogalactopyranoside) — and the cells begin producing the target peptide.
Harvesting and purification. Cells are lysed (broken open), and the target peptide is isolated from the cell contents through a series of chromatographic steps. Affinity chromatography using a fusion tag (such as His-tag or GST-tag) is commonly employed for initial capture, followed by tag cleavage and further polishing steps.
Expression Systems
| Host System | Advantages | Limitations |
|---|---|---|
| E. coli | Fast growth, high yield, low cost, well-characterized | No glycosylation, inclusion body formation, endotoxin contamination |
| Yeast (Pichia pastoris) | Some post-translational modifications, secretion into media | Hyper-glycosylation possible, slower than E. coli |
| Mammalian cells (CHO, HEK293) | Human-like post-translational modifications | Expensive, slow, lower yields |
| Insect cells (Sf9) | Complex protein folding, some modifications | Moderate cost, non-human glycosylation |
Endotoxin Considerations
A critical concern with E. coli-derived recombinant peptides is endotoxin contamination. E. coli is a gram-negative bacterium, and its outer membrane contains lipopolysaccharide (LPS), a potent pyrogen. Rigorous endotoxin removal and testing (typically by the LAL assay) is mandatory for any recombinant product intended for injection.
Recombinant vs. Synthetic
The choice between recombinant production and chemical peptide synthesis depends on several factors:
- Length — Chemical synthesis becomes exponentially more difficult and expensive above approximately 50 residues. Recombinant production handles hundreds of residues routinely.
- Modifications — Chemical synthesis allows non-natural amino acids and site-specific chemical modifications. Recombinant production is limited to the 20 standard amino acids (plus selenocysteine) and post-translational modifications the host cell can perform.
- Scale — Both methods can operate at large scale, but recombinant production is generally more cost-effective for longer peptides.
- Purity profile — Synthetic peptides may contain truncation and deletion sequences; recombinant peptides may contain host cell proteins, endotoxins, and residual DNA as contaminants.
Relevance to Peptide Research
Many peptides encountered in research settings are recombinantly produced:
- IGF-1 (70 amino acids) and growth hormone (191 amino acids) are produced recombinantly because their length makes chemical synthesis impractical
- Recombinant insulin was the first commercially available recombinant biologic, approved in 1982
- Shorter peptides such as BPC-157 (15 amino acids) are typically produced by chemical SPPS rather than recombinant methods, as the short chain length makes synthesis more economical
When evaluating a recombinant peptide product, the certificate of analysis should document host cell protein content, endotoxin levels, residual DNA, and purity by SDS-PAGE or HPLC.
Related Terms
Recombinant production is an alternative to chemical peptide synthesis and SPPS. Products must be tested for endotoxin contamination. Quality documentation is provided via a certificate of analysis.
Related entries
- Bioavailability— The percentage of an administered compound that reaches systemic circulation in its active form, heavily influenced by the route of administration.
- Certificate of Analysis (COA)— A quality assurance document issued by a laboratory that verifies the identity, purity, and composition of a peptide product through standardized analytical testing methods.
- Endotoxin— A toxic component of gram-negative bacterial cell walls (lipopolysaccharide) that serves as a critical contamination marker in injectable peptide products, detected by the LAL assay and subject to strict regulatory limits.
- Peptide Synthesis— The chemical or biological process of creating peptides by linking amino acids in a defined sequence, primarily through solid phase peptide synthesis (SPPS) using Fmoc or Boc protection chemistry.
- Solid Phase Peptide Synthesis— A method of peptide manufacturing in which amino acids are sequentially coupled to a growing chain anchored to an insoluble resin, enabling efficient synthesis, washing, and purification of defined peptide sequences.